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Biological actions of drug solvents
Abstract
Many biologic agents are weakly soluble in water. Therefore, they should
be dissolved in organic lipophilic solvents (vehicles). A drug vehicle is a sub-
stance of no therapeutic value that is used to convey an active biological
agent to the site of its action. Ideally, it should be biocompatible, 100% reli-
able, with no biological effect per se. However, presently used vehicles have
pleiotropic effects, which are often unknown to researchers, and often cause
misleading conclusions. In this review we summarize data on biological ef-
fects of the three most commonly used lipophilic drug vehicles dimethyl-
sulfoxide (DMSO), propylene glycol (PG) and ethanol. Besides in experi-
mental models, the data, where available, are shown on effects of solvents in
therapeutic use in humans. In conclusion, some recommendations are given
on the use of drug solvents in experiments.
INTRODUCTION
Many biologic agents are weakly soluble in water. Therefore, theyshould be dissolved in organic lipophilic solvents (vehicles). A
drug vehicle is a substance of no therapeutic value that is used to convey
an active biological agent to the site of its action. Ideally, it should be
biocompatible, 100% reliable, with no biological effect per se. How-
ever, presently used vehicles have pleiotropic effects which are often
unknown to researchers, often causing misleading conclusions. The
aim of this review is to summarize data on biological effects of the
three most commonly used lipophilic drug vehicles: dimethylsul-
foxide (DMSO), propylene glycol (PG) and ethanol. The main effects
of these agents are briefly summarized in Table 1.
DMSO
DMSO is one of the most common solvents used experimentally to
dissolve hydrophobic substances for in vivo and in vitro purposes. The
toxicity of DMSO is low: LD50 in mice is 6.2 mL/kg (when applied
intraperitoneally (i.p)) or 3.7 mL/kg (applied intravenously (i.v.)),
LD50 in rats is 9.9 mL/kg (i.p) or 7.4 mL/kg (i.v.) (1). However,
DMSO by itself has a variety of biological actions which can con-
found the effects of drugs when DMSO is used as a vehicle. The high-
est given dose of DMSO (when used as a vehicle) which we found in
literature was 6 mL/kg (2). It is noteworthy that some of the investiga-
tions cited in this review, found a substantial effect even with doses as
low as 0.1 mL/kg (3).
Through its anti-inflammatory, anti-coagulant and reactive oxygen
species scavenger activity, DMSO affects many organs, but it also has
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Overview
DMSO attenuates traumatic brain (4) and spinal injury
(5), brain edema (6) and ischemic brain injury (7, 8).
Neuroprotective effects of DMSO may be the result of
synergy (interplay) of various contributing factors: it sup-
presses inflammation, scavenges free radicals, it is a po-
tent diuretic, blocks Na+ channel activation and attenua-
tes Ca2+ current, it decreases tissue factor (TF) expression
and reduces thrombus formation… (9-12).
In contrast to this, one investigation in rats showed
that DMSO, if given consecutively for 10 days, can cause
reduction in nerve conduction velocity (in lower dose)
and myelin disruption with uncompacted myelin la-
melle (in higher dose) (13). Kleindienst et al. reported
that DMSO may promote brain edema through increas-
ing permeability of blood brain barrier (14).
Antinociceptive effects of DMSO have also been re-
ported. DMSO has analgesic effect comparable to mor-
phine, but the effect is not mediated through its action on
opioid receptors because it cannot be blocked by naloxone
(15). Coadministration of DMSO with morphine inter-
feres with antinociceptive effect of morphine; it seems that
acute administration of DMSO enhances, and chronic
administration, inhibits the effects of morphine (16).
Matheus et al. showed in‘ rats that DMSO, injected into
the dorsal periaqueductal grey, acts anxiolytically (17).
DMSO inhibits acetylcholinesterase (AChE) activity;
1) it can potentiate effects of acetylcholine on the heart
(18) and 2) it can reverse neuromuscular blockade cau-
sed by tubocurarine (19).
Cardiopreotective effects of DMSO in myocardial is-
chemia have also been reported (20, 21). Most probable
mechanisms of cardioprotection include its powerful in-
hibitory effect on platelet aggregation and suppression of
TF expression, but other mechanisms, such as blockade
of Ca2+ and Na+ influx, can also contribute to cardiopro-
tection (10).
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TABLE 1
Brief summary of the reported effects of DMSO, PG and ethanol on various organs.
Organ DMSO PG Ethanol
CNS protects from traumatic or
ischemic brain and spinal
injury (4, 5, 7,8)
Antinociceptive and anxyolytic
effect (15, 17)
AChE inhibition (18, 19)
Protects from seizures caused




Low doses protect from traumatic
or ischemic brain injury (91, 96,
97), high doses are detrimental
(94, 95)
Heart Protects from myocardial
ischemia (10)
Reduces arrhythmias induced by
strophanthin, barium chloride,
aconitine or adrenaline (79, 80).
Effect on ischemia/reperfusion
injury is controversial (109–115)
Decreases action potential
amplitude (116).
Liver Induces CYP450 (22, 23)
Protects from APAP, LPS,
halothane and chloroform




Protects from APAP (69) toxicity
(25, 69, 81)
Given acutely protects from LPS
and APAP (135-136, 139), when
given chronically has hepatotoxic
effect (137, 138, 140), Induces
CYP450 (140)
Kidney Protects from mercuric-
-chloride (34) and
gentamicin toxicity (35)
In high doses causes proximal
tubular cell injury (83)
Protects from salt-induced
hypertension (144)




Protects from mucosal injury
caused by cysteamine (37),




Immune system Mainly immunoinhibitory:
inhibits NF-kB (31, 43), induced
lymphocyte apoptosis (46),
protects from sepsis (43, 45)
Activates NK and NKT cells
in liver (47)
Immunoinhibitory: inhibits
macrophage, NK cell and





















DMSO treatment strongly induces expression and ac-
tivity of phase 1 (CYP450) and phase 2 (UDP glucuro-
nosyltransferases) drug-metabolizing liver enzymes (22,
23). However, the presence of DMSO during the drug
activation often inhibits drug metabolism in the liver,
probably by inhibiting the interaction of enzymes and
xenobiotics (23, 24), Due to this effect, DMSO treatment
can protect the liver from hepatotoxic agents that require
bioactivation by CYP enzymes.
The effect of DMSO varies in different models. DMSO
strongly protects against acetaminophen (APAP)-indu-
ced liver injury if applied before APAP, but it does not
protect when applied 2 h after APAP (when bioactivation
of APAP is completed) (3, 24, 25). On the other hand, it
protects from halothane and chloroform toxicity even
when applied 10–24 hours after poisoning, thus in this
model the hepatoprotection cannot be solely explained
by the blockade of bioactivation (26-28). Interestingly,
DMSO has no, or very low, effect on carbon tetrachloride
toxicity (23, 29); this is explained by the high affinity of
carbon tetrachloride for the lipophilic CYP enzyme site
(23). The protective effect of DMSO was also shown in
models of liver injury caused by D-galactosamine (30),
by simultaneous injection of D-galactosamine and lipo-
polysaccharide (LPS) (31) (in this model, high doses of
DMSO are required for protection; we achieved no pro-
tection with a dose of 0.6 mL/kg (25) and by ischemia-
-reperfusion (32). In these models there is no need for
P450 metabolism, thus not all hepatoprotective activity
of DMSO can be explained by CYPs inhibition. Protec-
tion in these models seems to be mediated through re-
duced nuclear factor kappa B (NF-kB) activation and
anti-oxidative activity (31). DMSO also blocks the me-
tabolism of various barbiturates and prolongs the sleep-
ing time caused by these drugs (33).
Nephroprotective actions of DMSO have been re-
ported in different models: it protects kidneys from mer-
curic-chloride (34) and gentamicin-induced injury (35).
Nephroprotection in these models is probably the result
of its anti-inflammatory and antioxidant effects. Protec-
tion against succinimide-induced kidney injury seems to
be the result of the blockade of succinimide biotransfor-
mation in to its active metabolites N-(3,5-dichlorophe-
nyl)-2-hydroxysuccinimide (NDHS) and N-(3,5-dichlo-
rophenyl)-2-hydroxysuccinamic acid (NDHSA), since it
was shown that DMSO is unable to protect kidneys
against injury caused by direct injection of these metabo-
lites (36).
Various investigations showed that DMSO protects
stomach and duodenum from mucosal injury caused by
cysteamine (37), by non steroid analgesic drugs (38-40),
by stress (38, 41) and by ethanol (40). The proposed me-
chanism is scavenging of hydroxyl radicals (OH) (39, 41).
However, Sorbye et al. reported that DMSO per se is a
gastric irritant and causes mucosal-gastric injury and
proposed that the protection achieved by DMSO in pre-
viously mentioned models is the result of »adaptive
cytoprotection« rather than of an oxyradical scavenger
effect (42).
It has been is generally accepted that the effect of
DMSO on the immune system is anti-inflammatory,
through the inhibition of NF-kB it suppresses tumor ne-
crosis factor alpha (TNF-a) formation and reduces In-
ter-Cellular Adhesion Molecule 1 (ICAM-1) expression
(31, 43, 44). Its protective role was shown in various
models of sepsis (43, 45). Intraperitoneal treatment of
rats with DMSO induced lymphocyte apoptosis in the
thymus, spleen, and Peyer’s patches (46). However, the
immunostimulatory effect of DMSO was observed in a
few studies. For example, it activated natural killer (NK)
and natural killer T (NKT) cells in mice liver (47) and
augmented the immune response to Sindbis virus infec-
tion in a mouse model by increasing the antibody titers
and serum interferon gamma (IFN-g) levels (48).
DMSO induces differentiation in many tumor cell
lines (49-51), most notably HL-60 (from promyelocytic
leukemia cells to mature granulocyte), probably by down-
-regulation of c-Myc expression (51). However, an oppo-
site effect was described in a few cell lines: DMSO inhibi-
ted differentiation of human trophoblast cells and pro-
moted invasiveness and metastatic potential of epithe-
lial-cell lines. This is possibly mediated through increa-
sed methylation of DNA; methyl radicals are generated
by the reaction of OH– radicals with DMSO (52, 53).
DMSO is not a good solvent for cisplatin, because these
two substances react and form an adducted compound
with reduced cytotoxicity (54).
In humans, the use of DMSO was considered as ther-
apy in various pathological conditions such as amyloido-
sis, gastrointestinal disorders, brain edema, stroke, brain
and spinal injury, rheumatoid arthritis, schizophrenia
(55-58). The only indication currently approved by the
United States Food and Drug Administration (FDA) is
treatment of interstitial cystitis by intravesical instillation
(59). DMSO is also used as a cryoprotectant in the
freezing and long-term storage of embryonic stem cells
and hematopoietic stem cells. Side effects described after
DMSO treatment include hemolysis, vomiting, nausea,
rash, flushing, bronchospasm and (very rarely) cardiac
arrest, stroke, encephalopathy, pulmonary edema or re-
nal failure (60). However, these side effects (except he-
molysis) (61). are mainly described on occasions when
human stem cells were transplanted with DMSO as a
carrier. Thus, for the most of the reported cases it is not
clear whether the side effect was caused by DMSO, or by
some other contributing factor. DMSO administration
causes garlic-like breath due to the pulmonary excretion
of its breakdown product dimethyl sulfide. This can
cause problems in double blinded studies, since the pa-
tients who received DMSO can be detected by odor (60).
PG
The toxicity of PG is low; LD50 in mice is 9.3 mL/kg
(when applied i.p) or 6.4 mL/kg (i.v.), in rats LD50 is 13
mL/kg (i.p) or 6.2 mL/kg (i.v.) (1). The highest given
dose of PG (when used as a vehicle) which we found in
the literature was 5 mL/kg. (62) The effects described in
our review occur with doses lower than this.
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Although there are much fewer reports about biologi-
cal effects of PG than for DMSO, PG is not completely
inert. PG has been shown to have inhibitory effects on
CNS: it reduces locomotor activity in mice; pretreatment
with PG delays the onset of seizure caused by exposure to
hyperbaric oxygen in cats (63) and by injection of penty-
lenetetrazol or strychnine in mice (64). Lin et al. showed
in rats that PG acts as an anxiolytical agent, but its
anxiolytyc potency was weaker than that of ethanol (65).
Prolongation of hypnotic effect of pentobarbital in ro-
dents (66) and enhancement of the sedative effect of di-
azepam in humans (67) have also been reported, but
these two effects are more likely caused by inhibitory ef-
fect of PG on CYP2E1 (68, 69) enzymes in the liver
(which metabolize diazepam and pentobarbital) than by
PGs' inhibitory effects on the CNS activity. In an is-
chemic stroke model of rat brain (70) Sood et al. found
that PG has protective effect on blood brain barrier after
a stroke. Hattori et al. reported that PG induces skeletal
muscle excitation in frogs and mice. In these experi-
ments, PG caused an increase in twitch tension and in
amplitude of the endplate potential. The authors as-
sumed that PG exhibits this action by facilitating trans-
mitter release from nerve terminals and by raising the
acetylcholine sensitivity of the muscle endplate (71, 72).
However, another explanation for this could be the in-
hibitory effect of PG on AChE activity. Such inhibitory
effect has already been reported for DMSO and some
other organic solvents (19, 73), but the effect of PG on
AChE activity has, to our best knowledge not been in-
vestigated.
PG causes pulmonary hypertension in sheep, possibly
through the release of thromboxane A2 (TXA2) (74).
Black et al. reported (1984) that administration of PG via
a nebulizer and face mask can prevent bronchoconstri-
ction induced by methoxamine in asthmatic patients
(75). On the contrary, a recent study by Choi et al. found
that children exposed to PG and PG ethers in bedroom
air have 1.5-fold greater likelihood of asthma (76). Simi-
larly, Wieslander et al. showed that short exposure to PG
mist from artificial smoke generators may cause acute oc-
ular and upper airway irritation in non-asthmatic sub-
jects and that a few of them may react with cough and
slight airway obstruction (77). Except for these three re-
ports, there are, to our best knowledge no other studies
on the influence of PG on asthma. Al-khudhairi et al. re-
ported that intravenous administration of PG to dogs
causes a transient decrease in heart rate and in arterial
pressure, possibly because of reflex stimulation of vagus
(78). PG prolongs effective refractory period and can re-
duce arrhythmias induced by strophanthin, barium chlo-
ride, aconitine, and adrenaline (79, 80).
PG strongly protects the liver from APAP toxicity be-
cause of its inhibitory effect on CYP2E1 enzymes which
are important for bioactivation of APAP to its toxic prod-
uct-NAPQI. It appears that PG does not inhibit CYP1A2
(25, 69, 81). As DMSO, PG blocks the metabolism of var-
ious barbiturates and prolongs the sleeping time caused
by these drugs (33, 64). Because some immunosuppre-
ssive effects of PG (see below) have been reported, we
investigated the effect of PG on the model of liver injury
induced by D-galactosamine and LPS, but found no ef-
fect. However, our investigation was conducted with a
low dose (0.6 mL/kg) of PG (25). The effect of PG on
hepatotoxicity of some other substances that require bio-
activation (halothane, chloroform, carbon tetrachloride)
has not been investigated. Investigations about the influ-
ence of PG on other models of liver injury are also lack-
ing. PG is metabolized by the liver to form lactate, ace-
tate, and pyruvate, lactic acidosis may occur after treat-
ment with PG (82).
Administration of high doses of PG to humans can
cause acute kidney injury, probably because of proximal
tubular necrosis; it was shown that proximal tubular
cell injury occurs in cultured human cells exposed to
PG (83).
Several immunoinhibitory actions of PG have been
reported. It inhibited the LPS activation of rat peritoneal
macrophages (84) and carrageenin-induced edema and
pleurisy, as well as granulomatous tissue formation (85).
Denning et al. showed that PG has inhibitory action on
NK cell and neutrophil function (86).
PG administration induced Heinz body formation in
cats and decreased red blood cell lifespan in adult cats in
a dose dependent manner (87).
In humans, several cases of PG poisoning have been
described after a treatment with a drug dissolved in PG
(typically lorazepam). Toxic effects include hyperosmo-
lality, increased anion gap metabolic acidosis (due to lac-
tic acidosis), acute kidney injury, and sepsis-like syn-
drome (88). In dermatology, it is known that topical PG
can cause allergic contact dermatitis (89).
Ethanol
Effects of ethanol are numerous and well investi-
gated. We will limit our review on actions which are most
likely to interfere with outcome in commonly used ex-
perimental models. LD50 in mice is 4 mL/kg (when ap-
plied i.p) or 2.8 mL/kg (i.v.), in rats LD50 is 6.3 mL/kg
(i.p) or 2.3 mL/kg. (i.v.) (1). The highest given dose of
ethanol (when used as a vehicle) which we found in the
literature was 1.65 mL/kg (90). Some of the effects de-
scribed in our review were obtained in investigations
with doses higher than this. We decided to indicate such
investigations rather than to omit them because in most
of them the lower dose of ethanol was not tested; it is
therefore not possible to exclude that the similar effect
would be obtained with a lower dose.
Ethanol is the CNS depressant, acting probably by in-
creasing the effects of the inhibitory neurotransmitter
GABA, although exact mechanisms are not fully under-
stood (91-93). The effect of ethanol on CNS-experimen-
tal models varies from protective to detrimental, depend-
ing on the experimental model and the dose of ethanol
applied. In a model of traumatic brain injury in rats, det-
rimental effect of the high doses of ethanol (higher than 2
mL/kg) was shown through an increase in cerebral ede-
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ma (94, 95). However, for lower doses of ethanol, most
investigations showed protective effect, possibly through
a decrease in pro-inflammatory cytokine production (96,
97). Persson et al. investigated the effect of acute ethanol
ingestion on cerebral-stab wounds in rats and found ag-
gravated injury in ethanol pretreated rats due to the in-
creased blood brain barrier permeability (98). It was con-
sidered that nimodipin and diazepam can protect against
cerebral hypoxia (99), but Moursi et al showed that the
protection was actually mediated by ethanol which was
used as a vehicle for these drugs (100). Titova et al
showed that ethanol protects against intracerebral hem-
orrhage induced by collagenase injection (101). IIda et al
showed that ethanol suppresses initial cerebral vasocon-
striction caused by cigarette smoking, possibly by attenu-
ating the smoking-induced TXA2 production (102).
A study by Obregon et al. which compared the effect
of various solvents per se on the cerebral AChE activity of
rats found that ethanol had no significant effect on AChE
activity even at 10% concentration and proposed ethanol
as the best organic solvent choice (73). However, Ro-
semberg et al. reported that ethanol exposure (1% in vol-
ume) during 1 h increased AChE activity in zebrafish
brain (103) and Owasoyo et al. reported that acute dose
of ethanol significantly decreased AChE activity in the
cerebral cortex of mice (104).
Low to moderate doses of ethanol are protective in a
model of ischemia followed by reperfusion in the CNS
and also in some other organs (small bowel, liver…) (91,
105-108), whereas the effect on ischemia/reperfusion in-
jury in heart remains controversial. Different mecha-
nisms for protective effect in this model of injury were
proposed. One of the possibilities is that ethanol stimu-
lates production of oxygen species which can induce or-
gans to initiate various mechanisms of protection. This
theory is supported by findings of Wang et al. that the
protective effect of ethanol in CNS can be inhibited by
apocynin, a specific inhibitor of NADPH oxidase (106).
Similarly, Yamaguchi et al. reported that the protective ef-
fect of ethanol against ischemia/reperfusion injury in the
small bowel of mice can be abrogated by administration
of some common antioxidants (108). On the other hand,
results of the experiments conducted by Qi et al. suggest
that ethanol exhibits its protective effects in the CNS by
enhancing GABA release and subsequently decreasing
c-Jun N-terminal kinase 3 (JNK3) activation (91, 107).
The effect of ethanol on ischemia/reperfusion injury
in the heart remains controversial. The chronic adminis-
tration of low and moderate doses of ethanol is consid-
ered to be protective against ischemic or ischemia/re-
perfusion injury in the heart. Zhou et al. showed that the
protective effect of chronic ethanol administration on
ischemia/reperfusion injury of the heart in rats can be
blocked by inhibition of protein kinase C epsilon (109),
and Pagel et al. showed the same for a blockade of the mi-
tochondrial K (ATP) channel (110). However, the role of
acute ethanol administration is controversial. Chen et al.
showed that a brief exposure of isolated adult rat cardiac
myocytes to 10–50 mM ethanol protects against the dam-
age induced by prolonged ischemia, and that this effect
could be blocked by inhibition of protein kinase C epsi-
lon (111). Churchill et al. reported a protective effect of
ethanol in vivo (0.5 g/kg, i.p.), when given 60 min prior
to a 30-minute transient ligation of the left anterior de-
scending coronary artery in rats (112). Similarly, Gross et
al. showed the protective effect of ethanol (0.25–0.5 g/kg,
i.v.) in dogs (113). However, Weber et al. could not repro-
duce these results (114). The difference between these
two experiments is that in the former dogs were anesthe-
tized and in the latter awake. The authors hypothesized
that the anesthesia could be the confounding factor (113,
114). Hale et al. found no protection with acutely admin-
istered ethanol in rabbits (115).
Beberova et al. investigated the changes of the action
potential (AP) configuration and ionic membrane cur-
rents in rat cardiomyocytes under ethanol exposure and
found decelerated upstroke velocity, decreased AP ampli-
tude and inhibition of the fast sodium current and l-type
calcium current and also a transient inhibition of out-
ward potassium current (116).
It is well known that ethanol acts in vasodilatory man-
ner on splanchnic blood vessels (117). However, it seems
that effects on blood vessels in brain, lungs, and possibly
in some heart vessels are mainly constrictive (118-120).
Doekel et al. showed that ethanol potentiates hypoxic
pulmonary vasoconstriction in dogs (121), and Lu et al.
showed that this effect can be blocked with a lipoxy-
genase inhibitor (122). Vasoconstrictive effect of ethanol
on pulmonary circulation has also been reported (123).
Most reports about effects of ethanol on cerebral blood
vessels suggest vasoconstrictive effect (119, 120); how-
ever, a few reports (Iida et al., for example) reported a
vasodilatory effect (102). Haves et al. showed that etha-
nol caused epicardial coronary artery vasoconstriction in
dogs (124). Vasoconstriction of carotid artery and aortic
ring after ethanol exposure was also reported (118, 119) .
Baraona et al. investigated the effect of ethanol on blood
flow in various organs in rats; ethanol (3 mg/kg, p.o.) in-
creased portal blood flow, but did not change the hepatic,
splenic or pancreatic arterial blood flows, it quadrupled
the coronary blood flow, doubled the renal flow and in-
creased cardiac output, but no significant changes in pul-
monary, cerebral or testicular flows were found. All these
effects of ethanol could be blocked with the nitric oxide
(NO) synthase inhibitor (125). Ethanol is known to in-
hibit platelet aggregation, possibly through inhibition of
phospholipase A2, resulting in a decrease in arachido-
nate metabolites, including TXA2, a potent stimulant of
platelet aggregation (126, 127). Ethanol inhibits platelet
aggregation mainly via transplasmalemmal Ca2+ entry-
-independent mechanisms (128).
Ethanol is known to trigger attacks of asthma in sus-
ceptible human individuals. Trevisani et al. showed that
ethanol treatment caused bronchoconstriction and in-
creased plasma extravasation in the guinea pig airways.
This action could be blocked by the inhibitor of the tran-
sient receptor potential vanilloid-1 (129). Because of its
immunosuppresive actions, ethanol can impair lung re-
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sistance to infection caused by Streptococcus pneumo-
niae, Pseudomonas aeruginosa and other microorgan-
isms (130, 131). Some possible mechanisms are negative
effects on neutrophils and NK cells, attenuation of in-
ducible NO synthase and cycloxigenase-2 induction, up-
regulation of IL-10 and downregulation of IL-12 (132,
133).
Acute ethanol treatment, performed a few hours be-
fore LPS, protects from LPS-induced liver injury; it
causes tolerance of Kupffer cells due to the downregu-
lation of toll-like receptor-4 and decreases production of
TNF-a (134-136). However, chronic ethanol treatment
has an opposite effect; it sensitizes Kupffer cells and ag-
gravates LPS-induced liver injury (134, 137, 138). These
effects were described for the the doses of ethanol greater
than 2 mg/kg. In a model of liver injury caused by simul-
taneous injection of D-galactosamine and LPS we found
no effect of a low dose of ethanol (0.6 mg/kg) (25). To our
best knowledge, there are no other reports about effects
of ethanol in this model. Wong et. al. showed that a con-
comitant single dose of ethanol (1 g/kg) protected mice
from hepatic injury induced by APAP, probably through
an inhibitory effect of ethanol on the biotransformation
of APAP to the toxic intermediate, an effect similar to
that of DMSO, that has been described previously (139).
In our experiments the dose of 0.6 mL/kg applied 30 min
before APAP had no influence. Chronic ethanol feeding
increases the hepatotoxicity of APAP probably through
an enhanced production of reactive metabolites since
ethanol is aknown inductor of microsomal enzymes (140).
Jaruga et al. showed that chronic ethanol administration
increased the susceptibility of mice to concanavalin A –
induced T cell-mediated hepatitis via upregulation of
the NF-kB signaling pathway (141). Acute and chronic
ethanol treatment potentiates the toxicity of chloroform
and carbon tetrachloride; this effect cannot be fully ex-
plained by induction of microsomal enzymes (142, 143),
Yamagishi et al. reported that a low dose of ethanol (1
mg/kg), given 15 min before gut ischemia, attenuated
ischemia-reperfusion liver injury and that a high dose (4
g/kg) had an opposite effect (105).
Vasdev et al. reported that the chronic consumption of
low doses of ethanol protects rats from salt-induced hy-
pertension (144). Several independent studies confirmed
that ethanol, given chronically at low doses, potentiates
the nephrotoxicity and neurotoxicity of methyl mercury
(145, 146). We could find no report about effects of etha-
nol on the commonest models of kidney injury induced
by gentamicin or cisplatin.
Ethanol treatment causes immunosuppression, in-
creasing susceptibility of animals to various microorgan-
isms. Ethanol inhibits the function of leukocytes (mono-
cytes, neutrophils, NK cells…) (147-150). Szabo et al.
showed that ethanol treatment reduces the levels of pro-
inflammatory cytokines (TNF-a and IL-1 beta) and in-
creases the levels of mediators with immunoinhibitory
potential, including transforming growth factor-beta and
IL-10 (147). Vinson et al. investigated whether the etha-
nol-caused suppression of neutrophil accumulation in
the peritoneal cavity of the rats can be explained by an
ethanol-induced increase in endogenous corticosterone.
However, ethanol maintained the suppressive effect even
when the action of corticosterone was blocked (148).
Other drug solvents
As we pointed out in Introduction, we have not dis-
cussed other drug solvents that are rarely used in experi-
ments or in therapeutic application of lipophilic drugs.
For example, we have shown that dimethylformamide is
highly protective in APAP-induced liver injury, but not in
the liver injury induced by simultaneous injection of
D-galactosamine and LPS (25).
In conclusion, in the effort to avoid a possible experi-
mental artifact with water-insoluble drugs, it is necessary
to reduce the amount of injected biologically active or-
ganic solvent (or reduce its concentration in vitro experi-
ments) to the minimum dose possible, use an organic
solvent with a smaller biological effect, or try to dissolve
the substance in aqueous solvent with changed pH or
ionic strength, warming and mixing the solution, etc.
Nonetheless, it is very important to include control
groups in which the effect of the drug vehicle alone is
tested. These principles were successfully applied for in-
vestigation of influence of high lipophilic eicosanoid de-
rivatives on APAP-induced liver injury in mice (151,
152).
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